Tipifarnib for the Treatment of Older Patients With AML
Harry Erba, MD, PhD, professor of medicine, director, Hematologic Malignancy Program, University of Alabama at Birmingham, discusses tipifarnib for the treatment of older, untreated patients with AML.
Clinical Pearls
Harry Erba, MD, PhD, professor of medicine, director, Hematologic Malignancy Program, University of Alabama at Birmingham, discusses tipifarnib for the treatment of older, untreated patients with acute myeloid leukemia (AML).
- Tipifarnib is a farnesyltransferase inhibitor
- Tipifarnib was studied in older, untreated patients with AML in a large, randomized phase II study
- This study accrued 348 patients to four different treatment arms in 15 months
- At the start of the study, there was little data showing that tipifarnib was effective
- This study recapitulated prior work, which showed a 15-20% response rate with tipifarnib
Considering the Durability of Zanubrutinib in Relapsed/Refractory CLL
April 11th 2024During a Case-Based Roundtable® event, Marc S. Hoffmann, MD, discussed his viewpoints on the use of Bruton tyrosine kinase inhibitors for patients with relapsed/refractory chronic lymphocytic leukemia and the efficacy behind zanubrutinib in the second article of a 2-part series.
Read More
